Avrobio Inc (AVRO)
US Market

Avrobio (AVRO) Stock Price & Analysis


AVRO Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.56 - $1.93
Previous Close$1.18
Average Volume (3M)2.12M
Market Cap
Enterprise Value-$1.95M
Total Cash (Recent Filing)$72.33M
Total Debt (Recent Filing)$18.34M
Price to Earnings (P/E)-0.5
Aug 10, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.31
Shares Outstanding44,105,078
10 Day Avg. Volume11,102,554
30 Day Avg. Volume2,124,811
Standard Deviation0.23
Financial Highlights & Ratios
Price to Book (P/B)0.96
Price to Sales (P/S)2262.78
Price to Cash Flow (P/CF)-0.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-42.33
Enterprise Value/Gross Profit-0.65
Enterprise Value/Ebitda0.02
Price Target Upside242.47% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4



Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Avrobio Inc’s price range in the past 12 months?
Avrobio Inc lowest stock price was $0.56 and its highest was $1.93 in the past 12 months.
    What is Avrobio Inc’s market cap?
    Currently, no data Available
    When is Avrobio Inc’s upcoming earnings report date?
    Avrobio Inc’s upcoming earnings report date is Aug 10, 2023 which is in 71 days.
      How were Avrobio Inc’s earnings last quarter?
      Avrobio Inc released its earnings results on May 11, 2023. The company reported -$0.57 earnings per share for the quarter, missing the consensus estimate of -$0.545 by -$0.025.
        Is Avrobio Inc overvalued?
        According to Wall Street analysts Avrobio Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Avrobio Inc pay dividends?
          Avrobio Inc does not currently pay dividends.
          What is Avrobio Inc’s EPS estimate?
          Avrobio Inc’s EPS estimate is -$0.56.
            How many shares outstanding does Avrobio Inc have?
            Avrobio Inc has 44,105,080 shares outstanding.
              What happened to Avrobio Inc’s price movement after its last earnings report?
              Avrobio Inc reported an EPS of -$0.57 in its last earnings report, missing expectations of -$0.545. Following the earnings report the stock price went down -2.985%.
                Which hedge fund is a major shareholder of Avrobio Inc?
                Among the largest hedge funds holding Avrobio Inc’s share is GMT Capital Corp. It holds Avrobio Inc’s shares valued at 4M.


                  Avrobio Stock Smart Score

                  The Avrobio stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Avrobio Inc

                  Avrobio, Inc. engages in the development of lentiviral-based gene therapies. It focuses on gene therapy for fabry, gaucher, pompe disease, and cystinosis. These gene therapies, on which the company was founded, were developed by Dr. Jeffrey Medin and Dr. Christopher Paige at the University Health Network. AvroBio launched in 2015, is headed by Co-Founder, President and CEO Geoff Mackay, and is headquartered in Cambridge, MA.


                  Top 5 ETFs holding AVRO

                  Market Value
                  Smart Score
                  iShares Core S&P Total U.S. Stock Market ETF
                  Up to five ETFs with an Outperform Smart Score that hold AVRO. The ETFs are listed according to market value of AVRO within the ETF


                  Forecast EPS vs Actual EPS

                  Similar Stocks
                  Price & Change
                  TScan Therapeutics
                  Protara Therapeutics
                  Unity Biotechnology
                  MAIA Biotechnology, Inc.

                  Popular Stocks

                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis